Back to Search
Start Over
Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements.
- Source :
-
The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2021 Oct; Vol. 6 (10), pp. 773-775. Date of Electronic Publication: 2021 Aug 03. - Publication Year :
- 2021
-
Abstract
- Competing Interests: I declare consultancy fees or honoraria from Pierre Fabre, Servier, Roche, AstraZeneca, Bristol Myers Squibb, Amgen, Merck, MSD, Novartis, Incyte Biosciences, Mylan, Baxter, Nutricia, and Fresenius Kabi, and research funding from Roche, and I am a coordinating investigator of academic clinical trials funded by OSE Immunotherapeutics and AstraZeneca.
Details
- Language :
- English
- ISSN :
- 2468-1253
- Volume :
- 6
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- The lancet. Gastroenterology & hepatology
- Publication Type :
- Academic Journal
- Accession number :
- 34358483
- Full Text :
- https://doi.org/10.1016/S2468-1253(21)00220-X